KR20230117341A - 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드 - Google Patents

다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드 Download PDF

Info

Publication number
KR20230117341A
KR20230117341A KR1020237016944A KR20237016944A KR20230117341A KR 20230117341 A KR20230117341 A KR 20230117341A KR 1020237016944 A KR1020237016944 A KR 1020237016944A KR 20237016944 A KR20237016944 A KR 20237016944A KR 20230117341 A KR20230117341 A KR 20230117341A
Authority
KR
South Korea
Prior art keywords
polypeptide
leu
lys
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237016944A
Other languages
English (en)
Korean (ko)
Inventor
디아즈 클라우디아 아니아 페나푸에르테
Original Assignee
큐라 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐라 테라퓨틱스, 인크. filed Critical 큐라 테라퓨틱스, 인크.
Priority claimed from PCT/US2021/055646 external-priority patent/WO2022086988A1/en
Publication of KR20230117341A publication Critical patent/KR20230117341A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237016944A 2020-10-20 2021-10-19 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드 Pending KR20230117341A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094277P 2020-10-20 2020-10-20
US63/094,277 2020-10-20
PCT/US2021/055646 WO2022086988A1 (en) 2020-10-20 2021-10-19 Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides

Publications (1)

Publication Number Publication Date
KR20230117341A true KR20230117341A (ko) 2023-08-08

Family

ID=81257992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016944A Pending KR20230117341A (ko) 2020-10-20 2021-10-19 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드

Country Status (8)

Country Link
US (2) US11407814B2 (https=)
EP (1) EP4232466A4 (https=)
JP (1) JP2023546298A (https=)
KR (1) KR20230117341A (https=)
CN (1) CN116615441A (https=)
AU (1) AU2021367306A1 (https=)
CA (1) CA3198822A1 (https=)
IL (1) IL302269A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
CN117120075A (zh) 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
EP3307783B1 (en) * 2015-06-10 2021-01-06 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
US20210061871A1 (en) 2019-08-29 2021-03-04 Nantbio, Inc. Modified N-810 and Methods Therefor
KR102402276B1 (ko) 2019-11-15 2022-05-26 주식회사 제넥신 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
TW202233661A (zh) 2020-10-20 2022-09-01 美商克拉治療股份有限公司 多功能及多價介白素-TGF-β受體融合多肽
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
CN117120075A (zh) * 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽

Also Published As

Publication number Publication date
AU2021367306A1 (en) 2023-06-01
CA3198822A1 (en) 2022-04-28
EP4232466A4 (en) 2024-11-06
EP4232466A1 (en) 2023-08-30
AU2021367306A9 (en) 2024-10-10
US12258383B2 (en) 2025-03-25
US20230023954A1 (en) 2023-01-26
IL302269A (en) 2023-06-01
JP2023546298A (ja) 2023-11-01
US11407814B2 (en) 2022-08-09
CN116615441A (zh) 2023-08-18
US20220127332A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US7947265B2 (en) Fusion proteins and methods for modulation of immune response
CN110461871B (zh) 白蛋白结合结构域融合蛋白
US10093710B2 (en) Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia
CN107074967A (zh) 白介素‑2/白介素‑2受体α融合蛋白和使用方法
KR20090008467A (ko) 치료용의 항체­표적 사이토카인
JP2021513570A (ja) サイトカインをコードするｒｎａを用いた治療
JP6682438B2 (ja) 癌治療のための改善された細胞組成物および方法
CN105209054A (zh) 使用白细胞介素-10治疗疾病和病症的方法
CN119604523A (zh) 正交gpc3嵌合抗原受体t细胞
JP2021535083A (ja) Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
US12258383B2 (en) Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
US20070299026A1 (en) Immunosuppressive Cytokine
WO2022086988A1 (en) Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
WO2020146773A1 (en) Methods of using il-2/cd25 fusion protein
WO2023276395A1 (ja) キメラサイトカイン受容体
NZ736967B2 (en) Use of il-15 to increase thymic output and to treat lymphopenia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230518

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241018

Comment text: Request for Examination of Application